**Activity Title:** CRN of Anywhere Winter Conference 2016  
**Activity Date:** January 16, 2016  
**Purpose Statement:** A conference to enhance the clinicians’ ability to make appropriate nutritional recommendations for his/her patients with chronic kidney disease (CKD) through the examination of the topics of amino acid solutions in peritoneal dialysis, hyperphosphatemia, and ESRD. This conference is intended for clinicians who nutritionally assess patients diagnosed with CKD.

### I. Educational Planning Table

Please note that sessions that are pre-approved by AND-CDR should not be listed.

<table>
<thead>
<tr>
<th>Objectives</th>
<th>Content (Outline of Topics)</th>
<th>Timeframe</th>
<th>Faculty</th>
<th>Teaching Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>Identify what the learner will know or be able to do following participation in the CE activity</td>
<td>Provide an outline of the topics that will be covered that correspond with each learning objective.</td>
<td>State the timeframe for each learning objective</td>
<td>List the Faculty for each learning objective</td>
<td>Describe the teaching methods, strategies, materials &amp; resources used for each learning objective</td>
</tr>
</tbody>
</table>

**Amino Acid Solutions in Peritoneal Dialysis (PD): Implication on Nutrition and the Peritoneal Membrane**

| Identify the causes of malnutrition in PD patients | • Description of PD  
• PD schedules  
• Profile and solution description  
• Advantages and disadvantages of PD  
• Dietary recommendations  
• Review of malnutrition in PD  
• Morbidity and mortality  
• Nutrition outcomes  
• Prevention and treatment | 40 minutes | James Davis, MD | PowerPoint, Case Study Presentation |

| Identify the role of intraperitoneal amino acid solutions (AA) in the treatment of malnutrition in PD patients | • Characteristics, composition, and pharmacokinetics  
• AA solution absorption, utilization | 20 minutes | James Davis, MD | PowerPoint, Case Study Presentation |
**Conventional PD Solutions:** changes and the consequences of the peritoneal structure  
- Vascular changes and peritoneal membrane dysfunction  
- Potential interventions to protect the peritoneal membrane integrity  
- AA solutions: benefits and potential side effects

### Hyperphosphatemia in End Stage Renal Disease (ESRD)

#### Describe the pathophysiology, lab indicators, and consequences of hyperphosphatemia

- Dietary Absorption of Phosphorus  
- Essential mineral  
- Bone and Mineral metabolism in CKD  
- Distribution of phosphate in the body, biochemical changes skeletal and cardiovascular effects  
- Glomerular Filtration rate (GFR) compensatory pathways  
- Diurnal variation in assessment of serum and urine phosphate  
- High and Low bone turnover  
- Limitations of phosphate as marker  
- Skeletal effects  
- Elevated phosphors is associated with an increased risk for dialysis; correlated with risk of incident CV disease  
- Burden of fractures  
- Correlation of calcified sites, increase mortality in observational studies

| Identify the guidelines and available treatment options for hyperphosphatemia | KDIGO Focus – normal treatment target ranges for phosphorus  
| --- | Changes in management patterns in Hemodialysis (HD) populations  
|  | Treatment Options |

<table>
<thead>
<tr>
<th>Time</th>
<th>Jessica Anderson, RD, LD</th>
</tr>
</thead>
<tbody>
<tr>
<td>40 minutes</td>
<td>PowerPoint, Figures, Slides</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Jessica Anderson, RD, LD</th>
</tr>
</thead>
<tbody>
<tr>
<td>20 minutes</td>
<td>PowerPoint, Figures, Graphs, Review of current published literature</td>
</tr>
</tbody>
</table>
### Evolution of phosphate binders

- Current treatment options and limitations of phosphate binders - Phosphate binders and survival of non-dialysis dependent, CKD patients and HD patients

### Vendor Exhibits

| Discuss new research and products available to assist renal practitioners in providing optimal care to their clients | Discussion with exhibitors (Pharma X, Pharma Y, Hospital X, Organization X, Organization Y, Organization Z) about products and research in the field of renal nutrition | 60 minutes | N/A | Interactive discussion |